11Mar 2025
TX vs. TE in HER2-Negative Breast Cancer: Comparable Efficacy, Differing Toxicities

TX vs. TE in HER2-Negative Breast Cancer: Comparable Efficacy, Differing Toxicities

A meta-analysis comparing docetaxel plus capecitabine (TX) and docetaxel plus epirubicin (TE) in HER2-negative breast cancer found no significant differences in survival or response rates. However, TX was linked to lower neutropenia risk but a higher incidence of hand-foot syndrome. These findings highlight the need for individualized treatment selection based on toxicity profiles.

  • #gynaecology - ivf

Like

Save

Share